Lilly´s strategy of sustaining a higher than average investment in R&D, at over 19 percent of sales annually, has enabled the company to invest heavily in visionary technologies such as systems biology, genomic medicine and bioinformatics.
This investment in R&D has translated into one of the most robust first-in-class and best-in-class pipelines in the industry. On the back of eight new medicines launched between 2003-2005, the company plans one new product submission in Europe in 2006 and have nine additional compounds and ten new indications anticipated in mid-to-late-stage development.
The UK has a proud history of medical discovery and the UK has played an important role in the Lilly research story.
The UK Research Centre was founded in 1967 and is where the company´s most successful ever product - Zyprexa® - was discovered. This medicine has already been used by more than 18 million patients world-wide.
Multidisciplinary development teams are dedicated to meeting unmet medical needs and are pursuing breakthrough medicines for Alzheimer´s disease, Parkinson´s disease, schizophrenia, and pain syndromes.
| 
About
